GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (STU:1K9) » Definitions » Debt-to-EBITDA

CareDx (STU:1K9) Debt-to-EBITDA : -1.34 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is CareDx Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CareDx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €5.5 Mil. CareDx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €21.5 Mil. CareDx's annualized EBITDA for the quarter that ended in Sep. 2024 was €-20.2 Mil. CareDx's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -1.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CareDx's Debt-to-EBITDA or its related term are showing as below:

STU:1K9' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.33   Med: -1.1   Max: 21.95
Current: -0.78

During the past 12 years, the highest Debt-to-EBITDA Ratio of CareDx was 21.95. The lowest was -2.33. And the median was -1.10.

STU:1K9's Debt-to-EBITDA is ranked worse than
100% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.805 vs STU:1K9: -0.78

CareDx Debt-to-EBITDA Historical Data

The historical data trend for CareDx's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Debt-to-EBITDA Chart

CareDx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.31 -2.22 -1.20 -0.64 -0.40

CareDx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.43 -0.58 8.48 -1.34

Competitive Comparison of CareDx's Debt-to-EBITDA

For the Diagnostics & Research subindustry, CareDx's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareDx's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CareDx's Debt-to-EBITDA falls into.



CareDx Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CareDx's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.45 + 25.931) / -77.871
=-0.40

CareDx's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.518 + 21.481) / -20.192
=-1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


CareDx  (STU:1K9) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CareDx Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CareDx's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CareDx Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

CareDx Headlines

No Headlines